Heartseed

CompanyJapan

Heartseed develops 2 assets, the furthest in phase 1 (HS-001 in heart failure). Mostly cell therapy; based in Japan.

2
Assets
Furthest stage
Phase 1
2
Trials
0
Signals

Pipeline

2
  • HS-001

    Transplanted allogeneic iPSC-derived cardiomyocyte spheroids regenerate heart muscle to improve cardiac function.

    Phase 1, Cell therapy, heart failure, ischemic heart disease

  • HS-005

    Transplanted allogeneic iPSC-derived cardiomyocyte spheroids regenerate heart muscle to improve cardiac function.

    Phase 1, Cell therapy, dilated cardiomyopathy, heart failure

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials2
  • Signals1
  • Similar companies6

Intelligence